Список литературы
1. Близнец Е.А., Викторова Е.А., Вишнева Е.А. и др. Наследственный ангионевротический отек: клинические рекомендации. 2020. Режимдоступа: https://raaci.ru/education/clinic_recomendations/102.html.
2. Maurer M. etal. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update // Allergy. 2018. Vol. 73.N. 8. P. 1575-1596.
3. Caballero T. et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations // J. Investig. Allergol. Clin. Immunol. 2011. Vol. 21.N. 6. P. 422-441.
4. Cicardi M. et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group //Allergy. 2014. Vol. 69.N. 5. P. 602-616.
5. Obtułowicz K. Bradykinin-mediated angioedema // Polish Arch. Intern. Med. 2016. Vol. 126.N. 1-2. P. 76-85.
6. Picard C. et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015 // J. Clin. Immunol. 2015. Vol. 35.N. 8. P. 696-726.
7. Bork K. et al. Guideline: Hereditary angioedema due to C1 inhibitor deficiency: S1Guideline of the German Society for Angioedema (Deutsche Gesellschaft fürAngioödeme, DGA), German Society for Internal Medicine (Deutsche Gesellschaft fürInnere Medizin, DGIM), German S // Allergo J. Int. 2019. Vol. 28.N. 1. P. 16-29.
8. Steiner U.C. et al. Hereditary angioedema due to C1-inhibitor deficiency in Switzerland:clinical characteristics and therapeutic modalities within a cohort study // Orphanet J. RareDis. 2016. Vol. 11.N. 1. P. 43.
9. Bork K. et al. Hereditary angioedema: new findings concerning symptoms, affectedorgans, and course // Am. J. Med. 2006. Vol. 119.N. 3. P. 267-274.
10. Zotter Z. et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency // Orphanet J. Rare Dis. 2014. Vol. 9.N. 44. P. 1-6.
11. Kaplan A.P., Joseph K. Pathogenesis of Hereditary Angioedema: The Role of theBradykinin-Forming Cascade // Immunol. Allergy Clin. North Am. Elsevier Inc, 2017.Vol. 37.N. 3. P. 513-525.
12. Giavina-Bianchi P. et al. Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis // Clinics. 2018. Vol. 73.
13. Germenis A.E. et al. International Consensus on the Use of Genetics in the Managementof Hereditary Angioedema // J. Allergy Clin. Immunol. Pract. 2019.
14. Aygören-Pürsün E., Bork K. Hereditäres Angioödem // Internist (Berl). 2019. Vol. 60.N. 9. P. 987-995.
15. Bork K. et al. Hereditary angioedema cosegregating with a novel kininogen 1 genemutation changing the N-terminal cleavage site of bradykinin // Allergy. 2019. Vol. 74.N. 12. P. 2479-2481.
16. Betschel S. et al. Canadian hereditary angioedema guideline // Allergy, Asthma Clin.Immunol. 2014. Vol. 10.N. 50. P. 1-18.
17. Bork K. et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study // Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology. 2011. Vol. 112.N. 1. P. 58-64.
18. Farkas H. et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor--a long-term survey // Allergy. 2012. Vol. 67.N. 12. P. 1586-1593.
19. Aygören-Pürsün E. et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II - the natural history // Allergy. 2013. Vol. 68.N. 8. P. 1034-1039.
20. Jurado-Palomo J. et al. Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency // J. Investig. Allergol. Clin. Immunol. 2013. Vol. 23.N. 1. P. 1-6.
21. Farkas H. et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency // Allergy Eur. J.Allergy Clin. Immunol. 2017. Vol. 72.N. 2. P. 300-313.
22. Farkas H. et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures // J. Oral Maxillofac. Surg. 1999. Vol. 57.N. 4. P. 404-408.
23. Sabharwal G., Craig T. Pediatric hereditary angioedema: an update // F1000Research. 2017. Vol. 6. P. 1205.
24. Prematta M. et al. Fresh frozen plasma for the treatment of hereditary angioedema // Ann.Allergy, Asthma Immunol. 2007. Vol. 98.N. 4. P. 383-388.
25. Peled M. et al. Preoperative prophylaxis for C1 esterase-inhibitor deficiency in patients undergoing oral surgery: a report of three cases // Quintessence Int. 1997. Vol. 28.N. 3. P. 169-171.
26. Atkinson J.C., Frank M.M. Oral manifestations and dental management of patients with hereditary angioedema // J. Oral Pathol. Med. 1991. Vol. 20.N. 3. P. 139-142.
27. Bouillet L. et al. Hereditary angioedema with normal C1 inhibitor: Clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a french cohort // Eur. J. Dermatology. 2017. Vol. 27.N. 2. P. 155-159.
28. Латышева Т.В. и др. Долгосрочная профилактика ангиоотѐков у пациентов с НАО //Российский аллергологический журнал. 2019. Т. 16. № 3. С. 75-83.
29. Magerl M. etal.HereditaryAngioedemawithNormalC1 Inhibitor // Immunol. Allergy Clin. North Am. 2017. Vol. 37. № 3. P. 571-584.
30. Bork K. et al. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII) // Allergy. 2017. Vol. 72.N. 2. P. 320-324.
31. Riedl M.A. et al. Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data // J. Allergy Clin. Immunol. Pract. Elsevier, 2016. Vol. 4.N. 5. P. 963-971.
32. Busse P. et al. Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients // J. Allergy Clin. Immunol. Pract. American Academy of Allergy,Asthma & Immunology, 2017. Vol. 5.N. 4. P. 1142-1145.
33. Fox J. et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema // Allergy Asthma Proc. 2017. Vol. 38.N. 3. P. 216-221.
34. Bygum A. et al. Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert® (C1-INH) Registry //Drugs and Aging. Springer International Publishing. 2016. Vol. 33.N. 11. P. 819-827.
35. Bork K., Hardt J. Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week // Int. Arch. Allergy Immunol. 2011. Vol.154.N. 1. P. 81-88.
36. Craig T. et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for longterm prophylaxis in hereditary angioedema // Allergy Rhinol. (Providence). 2017. Vol. 8.N. 1. P. 13-19.
37. Saule C. et al. Benefits of progestin contraception in non-allergic angioedema // Clin. Exp.
38. Allergy. 2013. Vol. 43.N. 4. P. 475-482.
39. Bouillet L. et al. Disease expression in women with hereditary angioedema // Am. J.Obstet. Gynecol. 2008. Vol. 199.N. 5. P. 484.e1-484.e4.
40. Maitrot-Mantelet L. et al. Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill // Horm. Mol. Biol. Clin. Investig. 2010. Vol. 3.N. 3. P. 441-447.
41. Bouillet L. et al. Traitements des angiœdèmes héréditaires: Recommandations du centre de référence national des angiœdèmes (consensus 2014de Bordeaux) // Press. Medicale. 2015. Vol. 44.N. 5. P. 526-532.
42. Longhurst H.J. Hereditary and other orphan angioedemas: A new prophylactic option at last? // Clin. Exp. Allergy. 2013. Vol. 43.N. 4. P. 380-382.
43. Инструкция по медицинскому применению лекарственного препарата такзайро. Зарегистрирована Минздравом России. 2021. 20 с.
44. Латышева Т.В., Латышева Е.А., Сетдикова Н.Х., Манто И.А. Персонифицированный подход - основа успеха терапии НАО с дефицитом С1-ингибитора // Поликлиника. 2020. № 1-2. С. 6-12.
45. Caballero T. et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency // J. Allergy Clin. Immunol. 2012. Vol. 129.N. 2. P. 308-320.
46. Bork K. et al. Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors, and therapy // J. Allergy Clin. Immunol. 2009. Vol.124.N. 1. P. 129-134.
47. Bork K., Fischer B., Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy // Am.J. Med. 2003. Vol. 114. N. 4. P. 294-298.